Opthea Scraps Flagship Drug, Pays $20M to Exit Funding Deal

TL;DR

**OPTEY is a high-risk bet after its lead drug failed, forcing a costly pivot and significant shareholder dilution.**

AI Summary

Opthea Ltd (OPTEY) reported a significant strategic shift for the fiscal year ended June 30, 2025, following the failure of its sozinibercept Phase 3 trials. The company discontinued the development of sozinibercept for wet AMD after its COAST and ShORe trials did not meet primary endpoints in March 2025. This led to a substantial operational streamlining, including workforce reductions and the termination of all clinical trial-related contracts. A critical financial event was the settlement of the Development Funding Agreement (DFA) with DFA Investors on August 19, 2025. Opthea made a cash payment of US$20 million and issued 136,661,003 ordinary shares, representing 9.99% of its then outstanding fully diluted share capital, to terminate the DFA. This restructuring indicates a pivot away from its primary drug candidate and a significant financial outlay to resolve prior commitments, impacting future revenue and net income projections. The company's future strategy will likely focus on new research and development opportunities, potentially targeting Vascular Endothelial Growth Factors (VEGF) C, D, and R3, as indicated in its forward-looking statements.

Why It Matters

Opthea's decision to discontinue sozinibercept development for wet AMD, its primary drug candidate, is a major setback for investors, signaling a complete pivot in its pipeline strategy. The US$20 million cash payment and issuance of 136,661,003 ordinary shares to terminate the DFA represent a significant financial burden and dilution for existing shareholders. This move places Opthea in a highly competitive biotech landscape without a lead clinical asset, forcing it to re-evaluate its entire business model. Employees face uncertainty due to workforce reductions, while customers and the broader market will see a delay in potential new treatments for wet AMD from Opthea.

Risk Assessment

Risk Level: high — The risk level is high due to the discontinuation of sozinibercept development after Phase 3 trial failures in March 2025, which was Opthea's primary product candidate. This led to a significant financial outlay of US$20 million cash and 136,661,003 ordinary shares (9.99% dilution) to terminate the DFA, indicating substantial financial and operational restructuring without a clear path forward for a lead asset.

Analyst Insight

Investors should exercise extreme caution and consider divesting, as Opthea faces significant uncertainty without a lead drug candidate and has incurred substantial costs to unwind previous commitments. New investors should avoid until a clear, viable pipeline strategy and funding plan are established.

Key Numbers

• $20M — Cash payment to DFA Investors (Part of the settlement to terminate the Development Funding Agreement on August 19, 2025.)
• 136,661,003 — Ordinary shares issued (Issued to DFA Investors as part of the DFA termination, representing 9.99% of outstanding shares.)
• 9.99% — Dilution to shareholders (Resulted from the issuance of ordinary shares to DFA Investors on August 19, 2025.)
• 1,231,817,008 — Ordinary Shares outstanding (Total ordinary shares outstanding as of June 30, 2025, including shares underlying ADSs.)
• 12,430,322 — American Depositary Shares outstanding (Total ADSs outstanding as of June 30, 2025.)
• 8 — Ordinary shares per ADS (Each American Depositary Share represents eight ordinary shares.)

Key Players & Entities

• Opthea Ltd (company) — Registrant
• Jeremy Levin (person) — Chairman and Chief Executive Officer
• DFA Investors (company) — Parties to Development Funding Agreement
• sozinibercept (company) — Discontinued drug candidate
• Nasdaq Global Select Market (regulator) — Exchange for ADSs
• Australian Securities Exchange (regulator) — Primary exchange for ordinary shares
• US$20 million (dollar_amount) — Cash payment to DFA Investors
• 136,661,003 (dollar_amount) — Ordinary shares issued to DFA Investors
• 9.99% (dollar_amount) — Dilution from shares issued to DFA Investors
• June 30, 2025 (dollar_amount) — Fiscal year end

FAQ

Risk Factors

• Failure of Phase 3 Trials and Strategic Pivot [high — operational]: The company's sozinibercept Phase 3 trials (COAST and ShORe) failed to meet primary endpoints in March 2025. This led to the discontinuation of development for wet AMD, a significant strategic shift impacting future operations and R&D focus.
• Development Funding Agreement Settlement [high — financial]: On August 19, 2025, Opthea settled its Development Funding Agreement (DFA) with DFA Investors by paying US$20 million in cash and issuing 136,661,003 ordinary shares. This settlement represents 9.99% of the then outstanding fully diluted share capital.
• Workforce Reductions and Contract Terminations [medium — operational]: Following the trial failures, Opthea underwent substantial operational streamlining, including workforce reductions and the termination of all clinical trial-related contracts. This indicates a significant restructuring of its operational capacity.
• Dilution from Share Issuance [medium — financial]: The issuance of 136,661,003 ordinary shares to DFA Investors as part of the settlement resulted in a 9.99% dilution to existing shareholders' fully diluted ownership.

Industry Context

The biopharmaceutical industry, particularly in ophthalmology, is characterized by high R&D costs and significant regulatory hurdles. Companies like Opthea focus on developing novel therapies for unmet medical needs, such as wet AMD. The competitive landscape involves established players and emerging biotech firms, with success often hinging on clinical trial outcomes and intellectual property.

Regulatory Implications

The failure of Phase 3 trials for sozinibercept highlights the inherent regulatory risks in drug development. Companies must navigate stringent FDA and EMA approval processes, where trial endpoints and safety profiles are critical. Any future development by Opthea will face similar rigorous scrutiny.

What Investors Should Do

1. Monitor future R&D pipeline announcements.
2. Evaluate the impact of the DFA settlement on cash runway.
3. Assess management's ability to identify and execute new development opportunities.

Key Dates

• 2025-03-01: Phase 3 Trials (COAST and ShORe) failed to meet primary endpoints — Led to the discontinuation of sozinibercept development for wet AMD and a major strategic shift for the company.
• 2025-08-19: Settlement of Development Funding Agreement (DFA) — Opthea paid US$20 million cash and issued 136,661,003 ordinary shares (9.99% dilution) to terminate the DFA, impacting cash reserves and share structure.

Glossary

sozinibercept

Opthea's drug candidate that was being developed for wet AMD. (Its failure in Phase 3 trials is the primary driver of the company's recent strategic and financial changes.)

wet AMD

Age-related macular degeneration, a leading cause of vision loss in people over age 60. (The primary indication for which sozinibercept was being developed.)

Development Funding Agreement (DFA)

An agreement related to funding development activities, the settlement of which involved a significant cash payment and share issuance. (The termination of this agreement on August 19, 2025, had a material financial impact on Opthea.)

ADSs

American Depositary Shares, representing ownership in ordinary shares of a non-U.S. company. (Opthea's shares trade in the U.S. as ADSs, with each ADS representing eight ordinary shares.)

IFRS

International Financial Reporting Standards, the accounting framework used by Opthea. (This is the basis for Opthea's consolidated financial statements, differing from U.S. GAAP.)

Year-Over-Year Comparison

The fiscal year ended June 30, 2025, marks a significant departure from the previous year due to the failure of Opthea's sozinibercept Phase 3 trials. This event triggered a substantial operational restructuring and a major financial settlement with DFA Investors, involving a $20 million cash payment and significant share issuance. Consequently, the company's financial trajectory and risk profile have fundamentally changed, moving away from a primary drug candidate towards potentially new R&D initiatives.

Key Financial Figures

• $20 million — Investors received a cash payment of US$20 million and 136,661,003 ordinary shares, equal

Filing Documents

• opt-20250630.htm (20-F) — 7503KB
• opt-ex4_19.htm (EX-4.19) — 137KB
• opt-ex4_20.htm (EX-4.20) — 133KB
• opt-ex4_21.htm (EX-4.21) — 149KB
• opt-ex4_22.htm (EX-4.22) — 293KB
• opt-ex12_1.htm (EX-12.1) — 16KB
• opt-ex12_2.htm (EX-12.2) — 16KB
• opt-ex13_1.htm (EX-13.1) — 12KB
• opt-ex15_1.htm (EX-15.1) — 5KB
• img93570987_0.jpg (GRAPHIC) — 5KB
• 0001193125-25-202743.txt ( ) — 30768KB
• opt-20250630.xsd (EX-101.SCH) — 2701KB
• opt-20250630_htm.xml (XML) — 8259KB

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No TABLE OF CONTENTS PRESENTATION OF FINANCIAL AND OTHER INFORMATION 4 ENFORCEMENT OF CIVIL LIABILITIES 6

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 7 PART I 9 Item 1. Identity of Directors, Senior Management and Advisers 9 Item 2. Offer Statistics and Expected Timetable 9 Item 3. Key Information 9 3A. Reserved 9 3B. Capitalization and Indebtedness 9 3C. Reasons for the offer and use of proceeds 9 3D.

Risk Factors

Risk Factors 9 Item 4. Information on the Company 62 4A. History and Development of Opthea 62 4B. Business Overview 62 4C. Organizational Structure 82 4D. Property, Plants and Equipment 82 Item 4A. Unresolved Staff Comments 82 Item 5. Operating and Financial Review and Prospects 83 5A. Operating Results 84 5B. Liquidity and Capital Resources 90 5C. Research and Development, Patents and Licenses 94 5D. Trend Information 94 5E. Critical Accounting Estimates 94 Item 6. Directors, Senior Management and Employees 99 6A. Directors and Senior Management 99 6B. Compensation 103 6C. Board Practices 108 6D. Employees 111 6E. Share Ownership 111 6F. Disclosure of a Registrant's Action to Recover Erroneously Awarded Compensation 112 Item 7. Major Shareholders and Related Party Transactions 112 7A. Major Shareholders 112 7B. Related Party Transactions 114 7C. Interests of Experts and Counsel 117 Item 8. Financial Information 117 8A. Consolidated Statements and Other Financial Information 117 8B. Significant Changes 117 Item 9. The Offer and Listing 117 9A. Offer and Listing Details 117 9B. Plan of Distribution 117 9C. Markets 117 9D. Selling Shareholders 117 9E.

Dilution

Dilution 117 9F. Expenses of the Issue 117 Item 10. Additional Information 118 10A. Share Capital 118 10B. Constitution 118 10C. Material Contracts 118 10D. Exchange Controls 118 10E. Taxation 118 10F. Dividends and Paying Agents 126 10G. 126 10H. Documents on Display 126 10I. Subsidiary Information 127 10J. Annual Report to Security Holders 127 Item 11.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 127 2 TABLE OF CONTENTS Item 12.

Description of Securities Other than Equity Securities

Description of Securities Other than Equity Securities 127 12A. Debt Securities 127 12B. Warrants and Rights 127 12C. Other Securities 127 12D. American Depositary Shares 127 PART II 130 Item 13. Defaults, Dividend Arrearages and Delinquencies 130 Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 130 Item 15.

Controls and Procedures

Controls and Procedures 130 Item 16 Reserved 131 16A. Audit Committee Financial Expert 131 16B. Code of Ethics 131 16C. Principal Accountant Fees and Services 131 16D. Exemptions from the Listing Standards for Audit Committees 132 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 132 16F. Change in Registrant's Certifying Accountant 132 16G. Corporate Governance 132 16H. Mine Safety Disclosure 133 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 133 16J. Insider Trading Policies 133 16K Cybersecurity 133 PART III 135 Item 17.

Financial Statements

Financial Statements 135 Item 18.

Financial Statements

Financial Statements 135 Item 19. Exhibits 135 3 presentation of financia l and other information Our reporting and functional currency is the U.S. dollar, and our financial statements included elsewhere in this Annual Report on Form 20-F, or annual report, are presented in U.S. dollars. The consolidated financial statements and related notes included elsewhere in this annual report have been prepared under the International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, which differs in certain significant respects from U.S. Generally Accepted Accounting Principles, or GAAP. Except where the context requires otherwise and for purposes of this annual report only: "ADSs" refers to our American depositary shares, each of which represents eight of our ordinary shares, no par value, and "ADRs" refers to the American depositary receipts that evidence our ADSs. "Opthea," "we," "us" "Group" "Company" or "our" refer to Opthea Limited and its subsidiaries. "A$" or "Australian dollar" refers to the legal currency of Australia. "IFRS" refers to the International Financial Reporting Standards as issued by the International Accounting Standards Board, or IASB. "AIFRS" refers to the Australian equivalents to International Financial Reporting Standards as issued by the Australian Accounting Standards Board, or AASB. "U.S. GAAP" refers to the Generally Accepted Accounting Principles in the United States. "EMA" refers to the European Medicines Agency "FDA" refers to the United States Food and Drug Administration. "US$" or "U.S. dollars" refers to the legal currency of the United States. "U.S." or "United States" refers to the United States of America. Except with respect to U.S. dollar amounts presented as contractual terms, amounts denominated in U.S. dollars when received or paid and unless otherwise indicated, certain Australian dollar amounts contained in this annual report have be

Identity of Dire ctors, Senior Management and Advisers

Item 1. Identity of Dire ctors, Senior Management and Advisers Not applicable.

Offer Statistics and Expected Timetable

Item 2. Offer Statistics and Expected Timetable Not applicable.

Key Information

Item 3. Key Information 3A. Re serve d 3B. Capitalization and Indebtedness Not applicable. 3C. Reasons for the off er and use of proceeds Not applicable. 3D. Risk Factors Investing in our securities involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as other information included in this annual report, including our consolidated financial statements and related notes included elsewhere in this annual report, before making an investment decision. If any of the following risks actually occur, it could harm our business, prospects, results of operations and financial condition. In such event, the trading price of the ADSs could decline and you might lose all or part of your investment. You should not interpret our disclosure of any of the following risks to imply that such risks have not already materialized. As described further in Item 4B. Business Overview, in March 2025, after the primary endpoints were not met in our COAST and ShORe Phase 3 trials, Opthea and the investors (the "DFA Investors") under our Development Funding Agreement (the "DFA") agreed to discontinue the development of sozinibercept in wet AMD, and agreed that this decision did not constitute a termination event under the DFA resulting in any amount payable by Opthea to the DFA Investors. Following the discontinuation of the clinical trials we streamlined our operations, reduced our workforce and Board of Directors and exited all contracts related to our clinical trials. We also entered into negotiations with the DFA Investors to settle the DFA. On August 19, 2025, we reached a binding agreement with the DFA Investors to terminate the DFA, pursuant to which the DFA Investors received a cash payment of US$20 million and 136,661,003 ordinary shares, equal to 9.99% of our then outstanding issued share capital on a fully diluted basis. Upon receipt of the cash payment and ordinary shares, the DFA Investors a

View Full Filing

View this 20-F filing on SEC EDGAR